Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO
, and has underlined competitive threats to a key pipeline candidate.
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.
Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.